Kenneth D. Paull

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index14.4kcitations83works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(26), Synthesis and biological activity(17), Computational Drug Discovery Methods(15), Synthesis and Biological Evaluation(10), Bioactive Compounds and Antitumor Agents(8)

Publications83 total

ChemInform Abstract: Mining and Visualizing Large Anticancer Drug Discovery Databases.
ChemInform·2000
Mining and Visualizing Large Anticancer Drug Discovery Databases
Journal of Chemical Information and Computer Sciences·1999· 87 cited
ChemInform Abstract: Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons.
ChemInform·1999
Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons
Journal of Medicinal Chemistry·1999· 133 cited
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
British Journal of Cancer·1998· 68 citedOpen Access
ChemInform Abstract: Mining the NCI Anticancer Drug Discovery Databases: Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues
ChemInform·1998
Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison
Molecular Pharmacology·1998· 167 cited
Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity
Molecular Pharmacology·1998· 78 cited
Mining the NCI Anticancer Drug Discovery Databases:  Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues
Journal of Chemical Information and Computer Sciences·1998· 105 cited
Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns
JNCI Journal of the National Cancer Institute·1997· 118 citedOpen Access
Analysis by CGH of the tumor cell lines of the NCI anticancer drug discovery screen
Cancer Genetics and Cytogenetics·1997· 1 cited
Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines
International Journal of Cancer·1997· 40 cited
Reduced folate carrier gene (RFC1) expression and anti‐folate resistance in transfected and non‐selected cell lines
International Journal of Cancer·1997· 3 cited
Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines
Nature Medicine·1997· 34 cited
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Science·1997· 1.2k cited
A protein expression database for the molecular pharmacology of cancer
Electrophoresis·1997· 86 cited
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
PubMed·1996· 79 cited
Identification of a Novel Inhibitor (NSC 665564) of Dihydroorotate Dehydrogenase with a Potency Equivalent to Brequinar
Biochemical and Biophysical Research Communications·1996· 13 cited
Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives
Biochemical Pharmacology·1996· 139 cited
Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Molecular Pharmacology·1995· 17 cited
page 1 of 5Next →

Frequent Co-authors

Anne Monks(12), Dominic A. Scudiero(12), John N. Weinstein(10), Jacqueline Plowman(9), V. L. Narayanan(9), Timothy G. Myers(8), Larry Rubinstein(8), Michael R. Boyd(6), Robert H. Shoemaker(5), Kurt W. Kohn(5), Ernest Hamel(5), Yves Pommier(5), Antonis D. Koutsoukos(4), Stephen Friend(3), N L Anderson(3), John K. Buolamwini(3), Edward A. Sausville(3), Daniel Zaharevitz(3), Vellarkad N. Viswanadhan(3), George R. Pettit(3)